News Summary

JBA AI, a leading health-tech division under AQ Pharmaceuticals, Inc. and JBA Brands, has achieved significant milestones in the realm of preventive healthcare. The platform has been recognized by the United States Food and Drug Administration (FDA) as a Software as a Medical Device (SaMD) and has also received Class B Medical Device approval from Vietnam’s Ministry of Health. This recognition underscores the platform’s safety and clinical efficacy on an international scale. JBA AI offers a mobile application that enables contactless monitoring of vital signs, delivering insights on various health metrics such as heart rate and blood pressure trends. The app uses AI-powered facial signal analysis and is available for Android, with plans for an iOS release. Founder and CEO Tracy Trang Nguyen, a Vietnamese American engineer, developed JBA AI following her personal health journey, integrating advanced AI with wellness solutions. The platform is expanding its reach through partnerships, including a significant collaboration with a major Vietnamese financial institution, and is gaining traction in various sectors such as pharmacies and corporate wellness programs across the globe.